The size of the Cancer Biomarkers Market in the Middle East & Africa was worth USD 1.15 billion in 2023 and estimated to be growing at a CAGR of 11.652% to reach USD 2.00 billion by 2028.
Biomarkers are used in imaging technology to offer precise imaging of oncology tumors and other problems and also eradicate the possibility of radiation exposure during imaging through CT scans and MRI scans. In addition, biomarkers facilitate pharmaceutical companies to analyze and discover novel drugs as demand for valuable and efficient treatment doses increases.
The cancer biomarkers market is expected to witness lucrative growth over the forecast period owing to the rising prevalence of cancer, improper diet, increasing consumption of tobacco, lack of physical activities, and many sun & UV exposures. Furthermore, the growing geriatric population base, raising awareness regarding the usage of biomarkers at various stages of cancers, and rising demand for clinical diagnosis in the early stages of cancers are some factors that are expected to boost usage rates.
The high cost of diagnostic procedures is restraining market growth.
This research report on the MEA Cancer Biomarkers Market segmented and sub-segmented into the following categories:
KEY MARKET PLAYERS:
Some of the prominent companies operating in the Middle East & Africa cancer biomarkers market profiled in this report are Abbott Laboratories, Agendia Bv, Biocurex Inc, Biomerieux S.A, Biomoda Inc., Astellas Pharma Us Inc., Correlogic Systems Inc., Beckman Coulter Inc., Becton, Dickinson and Company, Clarient Inc., Diadexus Inc., Ambrilia Biopharma, Affymetrix Inc and Aureon Laboratories Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org